Clinical and laboratory data in patients with SSc
| Clinical and laboratory data | Raised MCP-3 (n = 17) | Normal MCP-3 (n = 52) |
|---|---|---|
| Results are shown as percentages. | ||
| VC, vital capacity; Tlco, carbon monoxide transfer factor; ESR, erythrocyte sedimentation rate; CRP, C reactive protein. | ||
| *p<0.05, versus patients with SSc with normal MCP-3 levels. | ||
| Age at onset (years), mean (SD) | 53 (15) | 51 (17) |
| Male:female | 4:13 | 6:46 |
| Duration (years), mean (SD) | 2.6 (2.4) | 4.7 (5.1) |
| Clinical features | ||
| Contracture of phalanges | 88 | 40 |
| Pitting scars | 47 | 37 |
| Organ involvement | ||
| Lung | 88* | 35 |
| Decreased %VC | 47* | 19 |
| Decreased %Tlco | 76 | 52 |
| Oesophagus | 71 | 65 |
| Heart | 24 | 15 |
| Muscle | 12 | 17 |
| Laboratory findings | ||
| Anti-topoisomerase I antibody | 82* | 38 |
| Anticentromere antibody | 6* | 54 |
| Increased IgG | 41 | 23 |
| Raised ESR | 35 | 23 |
| Raised CRP | 0 | 15 |